ATRS
$4.02
Antares Pharma
$.04
1.01%
ATRS
Earnings Whisper ®
N/A
4th Quarter December 2019
Consensus:  $0.00
Revenue:  $31.41 Mil
Thursday
Feb 27
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Guidance announcement made Tuesday, November 05, 2019

What do you expect when ATRS reports earnings?
Beat
Meet
Miss

Where is ATRS's stock price going from here?
Up
Flat
Down
Stock chart of ATRS
Analysts
Summary of analysts' recommendations for ATRS
Score
Grade
Pivots
Resistance
$4.28
$4.20
$4.09

$4.01

Support
$3.90
$3.82
$3.71
Tweet
Growth
Description
Antares Pharma, Inc. develops, commercializes and markets novel delivery solutions, including needle-free and mini-needle injector systems, gel technologies and transdermal products, which improve both the efficiency of drug therapies and the quality of life for patients. The Company currently distributes its needle-free injector systems for the delivery of insulin and growth hormone in over 20 countries and an estradiol transdermal patch for hormone replacement therapy.
Peers
StrykerBoston ScientificBecton, DickinsonBaxter InternationalWatersTeleflexAbbott Laboratories3MIntegra LifeSciences HoldingsAbiomed